CRSP
Crispr Therapeutics AG
55.40$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -99.7% | +2.6% | +16.4% | +5,714.0% | -97.5% | +3.1% | -0.3% | -2.8% | +68.8% | +598.3% | – | |
| – | -14.6% | +159.0% | +10.0% | -72.0% | -74.0% | +1,285.4% | -13.5% | +30.0% | -8.2% | -15.4% | -11.3% | – | |
| – | – | -128.5% | – | – | – | -261.8% | – | – | – | – | – | – | |
| – | +4.9% | -25.0% | +5.6% | +2.7% | +6.2% | -11.8% | -9.9% | -9.8% | +32.2% | -11.9% | -5.3% | – | |
| – | -9.9% | +8.9% | +8.5% | -10.6% | +4.0% | +6.5% | -2.0% | -10.5% | +8.7% | -6.6% | +2.2% | – | |
| – | +1.3% | -19.1% | +6.2% | 0.0% | +5.1% | -7.8% | -8.2% | -18.9% | +41.0% | -15.4% | -1.3% | – | |
| – | – | -302.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -229.3% | – | – | – | – | – | – | – | – | – | – | |
| – | -43.4% | +210.7% | +77.8% | -31.9% | -20.1% | +58.4% | +16.5% | -52.1% | -0.8% | +36.6% | +14.4% | – | |
| – | – | -230.5% | – | – | – | – | – | – | – | – | – | – | |
| – | – | -217.5% | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.